121 related articles for article (PubMed ID: 10190794)
1. Paclitaxel-based treatment of lymphoma.
Younes A
Semin Oncol; 1999 Feb; 26(1 Suppl 2):123-8. PubMed ID: 10190794
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
[TBL] [Abstract][Full Text] [Related]
3. Role of paclitaxel in the treatment of breast cancer: the American Cooperative Group Experience.
Sledge GW
Semin Oncol; 1996 Feb; 23(1 Suppl 1):10-2. PubMed ID: 8629029
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel in the treatment of hormone-refractory prostate cancer.
Smith DC; Pienta KJ
Semin Oncol; 1999 Feb; 26(1 Suppl 2):109-11. PubMed ID: 10190791
[TBL] [Abstract][Full Text] [Related]
6. Review and outlook for the role of paclitaxel in urothelial carcinoma.
Vaughn DJ
Semin Oncol; 1999 Feb; 26(1 Suppl 2):117-22. PubMed ID: 10190793
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
8. The evolving role of paclitaxel for patients with carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1999 Feb; 26(1 Suppl 2):129-33. PubMed ID: 10190795
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel (Taxol) for the treatment of head and neck cancer.
Forastiere AA
Semin Oncol; 1994 Oct; 21(5 Suppl 8):49-52. PubMed ID: 7939763
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel in the treatment of esophageal cancer.
Weiner LM
Semin Oncol; 1999 Feb; 26(1 Suppl 2):106-8. PubMed ID: 10190790
[TBL] [Abstract][Full Text] [Related]
11. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer.
Hortobagyi GN; Holmes FA; Ibrahim N; Champlin R; Buzdar AU
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S30-3. PubMed ID: 9071338
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
Paridaens R
Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
[TBL] [Abstract][Full Text] [Related]
15. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
Rizzieri DA; Sand GJ; McGaughey D; Moore JO; DeCastro C; Chao NJ; Vredenburgh JJ; Gasparetto C; Long GD; Anderson E; Foster T; Toaso B; Adams D; Niedzwiecki D; Gockerman JP
Cancer; 2004 Jun; 100(11):2408-14. PubMed ID: 15160345
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.
King K; Younes A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):14-22. PubMed ID: 10697039
[TBL] [Abstract][Full Text] [Related]
17. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel: current developmental approaches of the National Cancer Institute.
Arbuck SG
Semin Oncol; 1995 Dec; 22(6 Suppl 15):55-63. PubMed ID: 8643972
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel plus nonanthracycline combinations in metastatic breast cancer.
Perez EA
Semin Oncol; 1999 Feb; 26(1 Suppl 2):21-6. PubMed ID: 10190781
[TBL] [Abstract][Full Text] [Related]
20. The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma.
Cabanillas F
Semin Hematol; 1999 Oct; 36(4 Suppl 8):11-5. PubMed ID: 10622224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
